FDA approves new pancreatic cancer drug that could transform treatments

The Food and Drug Administration (FDA) approved a pancreatic cancer drug experts predict could transform treatment for the deadly disease. Rasonque, or Daraxonrasib, was approved for patients with advanced pancreatic cancer who have already tried a prior treatment like chemotherapy. The drug is a daily pill that helps target a mutation in a gene called KRAS. This gene is found in almost all pancreatic cancers as well as other cancers, such as lung, colorectal and ovarian.

Rachna Shroff, MD, a Gastrointestinal Oncologist from Banner University Medicine, joined “Arizona Horizon” to discuss how this drug could change outcomes for this disease.